ICON PLC (NASDAQ:ICLR) had its target price lifted by Jefferies Group LLC from $122.00 to $132.00 in a report released on Monday morning. Jefferies Group LLC currently has a buy rating on the medical research company’s stock. Jefferies Group also issued estimates for ICON PLC’s Q3 2018 earnings at $1.47 EPS, FY2018 earnings at $5.83 EPS and FY2019 earnings at $6.43 EPS.
Other analysts also recently issued reports about the stock. BidaskClub raised shares of ICON PLC from a hold rating to a buy rating in a report on Friday, June 23rd. SunTrust Banks, Inc. raised shares of ICON PLC from a hold rating to a buy rating and increased their price target for the stock from $93.00 to $126.00 in a report on Monday, July 31st. Credit Suisse Group reissued a buy rating on shares of ICON PLC in a report on Friday, July 28th. Zacks Investment Research raised shares of ICON PLC from a hold rating to a buy rating and set a $120.00 price target on the stock in a report on Thursday, August 24th. Finally, ValuEngine raised shares of ICON PLC from a hold rating to a buy rating in a report on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $117.33.
Shares of ICON PLC (NASDAQ ICLR) opened at 114.85 on Monday. ICON PLC has a 12 month low of $73.76 and a 12 month high of $117.53. The stock’s 50 day moving average is $112.86 and its 200 day moving average is $97.82. The company has a market capitalization of $6.21 billion, a P/E ratio of 23.30 and a beta of 0.59.
ICON PLC (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.01. ICON PLC had a net margin of 15.97% and a return on equity of 28.72%. The firm had revenue of $431.00 million for the quarter, compared to the consensus estimate of $430.68 million. During the same period in the prior year, the firm posted $1.14 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities analysts predict that ICON PLC will post $5.32 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the business. Shine Investment Advisory Services Inc. acquired a new stake in shares of ICON PLC in the second quarter valued at about $103,000. Acrospire Investment Management LLC raised its position in shares of ICON PLC by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC raised its position in shares of ICON PLC by 20.7% in the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after buying an additional 217 shares during the last quarter. US Bancorp DE raised its position in shares of ICON PLC by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock valued at $154,000 after buying an additional 251 shares during the last quarter. Finally, Huntington National Bank raised its position in shares of ICON PLC by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after buying an additional 77 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with our FREE daily email newsletter.